News
Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA
Dr. Vicky Richon, Appointed to Board of Directors; Chris Guiffre Appointed President and Chief Operating Officer Newton, MA, Aug 10, 2023 – Auron Therapeutics, a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its AI-powered platform, today announced appointments to its board of directors and management team. Victoria Richon, Ph.D.,…
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer
Advisory Board includes recognized physicians, clinicians and scientists with deep expertise spanning multi-omic platforms, translational biology, drug discovery and clinical development Newton, MA, August 1, 2023 – Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular plasticity, today announced the members of its scientific advisory board (SAB), comprised…
Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform
Auron expands its leadership team with the appointments of David Millan, Ph.D., as Chief Scientific Officer, Thomas Graeber, Ph.D., as Chief Data Officer, Andrea Armstrong as Chief People Officer and Briggs Morrison, M.D., as Independent Chairman of the Board. Newton, Mass., July 20, 2022 — Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing therapies…
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
Wellesley, Mass., Jan. 27, 2021 – Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced the completion of its $12.75 million seed financing round. Proceeds will be used to discover and develop novel therapeutics directed toward differentiation therapy, which reactivates endogenous cellular programs to elicit tumor cell maturation…